TherapeuticsMD
TXMD
149 hedge funds and large institutions have $190M invested in TherapeuticsMD in 2020 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 46 increasing their positions, 37 reducing their positions, and 18 closing their positions.
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
24% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 37
5% more funds holding
Funds holding: 142 → 149 (+7)
0% more capital invested
Capital invested by funds: $190M → $190M (+$607K)
0.23% less ownership
Funds ownership: 1.35% → 1.12% (-0.23%)
20% less call options, than puts
Call options by funds: $847K | Put options by funds: $1.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.87M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$984K |
| 3 |
Millennium Management
New York
|
+$887K |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$848K |
| 5 |
Squarepoint
New York
|
+$836K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$13.7M |
| 2 |
JP Morgan Chase
New York
|
-$7.23M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$6.99M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.15M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.04M |
TXMD Hedge Fund Activity: Q2 2020 in Review
149 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q2 2020, worth a combined $190M — up 0.32% from $190M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TXMD positions and 18 closed out — a net gain of 8 holders — while 46 added to existing stakes and 37 trimmed.
The largest buyer was BlackRock, adding an estimated $3.87M. The largest seller was Bank of New York Mellon, cutting an estimated $13.7M.
- 149 institutional investors held TherapeuticsMD (TXMD) as of Q2 2020, up from 142 in Q1 2020.
- Funds reported $190M of TherapeuticsMD stock for Q2 2020, up 0.32% quarter-over-quarter.
- 26 funds opened new TherapeuticsMD positions in Q2 2020 and 18 closed out, a net change of +8 holders.
- The largest TherapeuticsMD buyer in Q2 2020 was BlackRock, an estimated $3.87M added.
- The largest TherapeuticsMD seller in Q2 2020 was Bank of New York Mellon, an estimated $13.7M sold.
Based on aggregated 13F filings for Q2 2020.